Home › Trial NCT04530227
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
- Trial IDNCT04530227
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorTianjin Medical University Cancer Institute and Hospital
- Enrollment30
- Start date2020-09-25
- ConditionsEarly Stage Non-small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.